Close Menu

NEW YORK (GenomeWeb) – NanoString Technologies reported after the close of the market today that its third quarter revenues were up seven percent year over year.

For the three months ended Sept. 30, NanoString's revenues were $30.6 million compared to $28.6 million in Q3 2018, beating the Wall Street estimate of $28.1 million.

The firm said it took in $26.3 million in product and service revenue in the quarter, a 23 percent increase from $21.5 million in Q3 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.